|
Product class:
|
Medicinal product with marketing authorization
|
|
Medicinal product class:
|
Veterinary medicine
|
|
Name of medicinal product:
|
Cepralock
|
|
Active substances:
|
|
|
ATC code:
|
QG52XX80
|
|
Dosage form:
|
intramammary suspension
|
|
Strength:
|
2,6g
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
|
Summary of product characteristics (SPC):
|
 (last updated 23 February 2021)
|
|
Package information leaflet (PIL):
|
EST (last updated 23 February 2021)
|
|
Labelling:
|
(last updated 23 February 2021)
|
|
Indication:
|
Prevention of new intramammary infections throughout the dry period.
In cows considered likely to be free of sub-clinical mastitis, the product can be used on its own in dry
cow management and mastitis control.
|
|
Safety features:
|
No
|
|
Marketing authorization holder:
|
Intervet International B.V.
|
|
Marketing authorization number:
|
2278
|
|
Marketing authorization issued on:
|
23 February 2021
|
|
Marketing authorization expires on:
|
23 February 2026
|
|
Marketing authorization procedure type:
|
Decentralised
|
|
Assessment report:
|
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
|
1809468
|
Cepralock
|
intramammary suspension
|
2,6g 24TK
|
Prescription
|
|
|
|
|
|
|
1809479
|
Cepralock
|
intramammary suspension
|
2,6g 144TK
|
Prescription
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription